• Publications
  • Influence
Prognosis of HIV-1-infected patients starting highly active antiretroviral therapy: a collaborative analysis of prospective studies
TLDR
The CD4 cell count at initiation was the dominant prognostic factor in patients starting HAART, and should be taken into account in future treatment guidelines. Expand
Pre-exposure prophylaxis to prevent the acquisition of HIV-1 infection (PROUD): effectiveness results from the pilot phase of a pragmatic open-label randomised trial
TLDR
In this high incidence population, daily tenofovir–emtricitabine conferred even higher protection against HIV than in placebo-controlled trials, refuting concerns that effectiveness would be less in a real-world setting. Expand
Initiation of Antiretroviral Therapy in Early Asymptomatic HIV Infection.
TLDR
The initiation of antiretroviral therapy in HIV-positive adults with a CD4+ count of more than 500 cells per cubic millimeter provided net benefits over starting such therapy in patients after the CD4+, but the risks of unscheduled hospital admissions were similar in the two groups. Expand
CD4+ count-guided interruption of antiretroviral treatment.
TLDR
Episodic antiretroviral therapy guided by the CD4+ count significantly increased the risk of opportunistic disease or death from any cause, as compared with continuous antireteviral therapy, largely as a consequence of lowering theCD4+ cell count and increasing the viral load. Expand
Decline in the AIDS and death rates in the EuroSIDA study: an observational study
TLDR
The initial drop in mortality and morbidity after the introduction of HAART has been sustained and potential long-term adverse effects associated with HAART have not altered its effectiveness in treating AIDS. Expand
Liver-related deaths in persons infected with the human immunodeficiency virus: the D:A:D study.
TLDR
A strong association between immunodeficiency and risk of liver-related death was found and long-term follow-up is required to investigate whether clinically significant treatment-associated liver- related mortality will develop. Expand
Combination antiretroviral therapy and the risk of myocardial infarction.
TLDR
Combination antiretroviral therapy was independently associated with a 26 percent relative increase in the rate of myocardial infarction per year of exposure during the first four to six years of use, however, the absolute risk of my Cardiac Infarction was low and must be balanced against the marked benefits from antireTroviral treatment. Expand
Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients enrolled in the D:A:D study: a multi-cohort collaboration
TLDR
There exists an increased risk of myocardial infarction in patients exposed to abacavir and didanosine within the preceding 6 months and the excess risk does not seem to be explained by underlying established cardiovascular risk factors and was not present beyond 6 months after drug cessation. Expand
Changing patterns of mortality across Europe in patients infected with HIV-1
TLDR
Death rates across Europe among patients infected with HIV-1 have been falling since September, 1995, and at the beginning of 1998 were less than a fifth of their previous level. Expand
Cardiovascular disease risk factors in HIV patients – association with antiretroviral therapy. Results from the DAD study
TLDR
Of specific concern is the fact that use of the NNRTI and PI drug classes (alone and especially in combination), particularly among older subjects with normalized CD4 cell counts and suppressed HIV replication, was associated with a lipid profile known to increase the risk of coronary heart disease. Expand
...
1
2
3
4
5
...